Gilead Sciences, Inc. (GILD) Stock Analysis
Is GILD a good investment?
Gilead Sciences, Inc. (GILD) has a Plutrex AI rating of 82.0/100 as of May 26, 2026, indicating a Strong Buy consensus. The stock is not classified as halal-compliant. Key strength: Exceptional profitability with ROE 43.2% and gross margin 79.4% significantly outperforming industry benchmarks. Main concern: Revenue growth of 4.4% lags industry average of 9.42% indicating potential market share pressures.
Investment Summary
GILD presents a compelling investment opportunity with exceptional profitability metrics (ROE 43.2%, gross margin 79.4%) trading at attractive valuation discount (PE 18.28 vs industry 28.66, 36.2% discount). The company demonstrates superior operational efficiency with net margin of 30.9% (63.6% premium to industry) while maintaining strong financial health with $9.8 billion cash and moderate debt-to-equity of 0.89. Recent FDA approval for HDV treatment and WHO collaboration expansion strengthen the growth narrative, supported by explosive forward EPS growth of 3577.4%.
Key Strengths
- Exceptional profitability with ROE 43.2% and gross margin 79.4% significantly outperforming industry benchmarks
- Attractive valuation discount at 36.2% below industry PE despite superior operational metrics
- Strong news momentum with FDA approval for HDV treatment and WHO collaboration expansion
Key Concerns
- Revenue growth of 4.4% lags industry average of 9.42% indicating potential market share pressures
- PEG ratio of 1.56 suggests moderate overvaluation relative to long-term growth expectations
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
GILD exhibits outstanding fundamental strength across key metrics. Profitability leadership is evident with ROE of 43.2% (vs typical 15-20% benchmark), gross margin of 79.4% (13.6% above industry 69.98%), and operating margin of 39.3% (17.6% above industry 33.40%). Financial health remains solid with $9.8 billion cash providing substantial liquidity, though debt-to-equity of 0.89 requires monitoring. Growth profile shows dramatic near-term acceleration (3577.4% next year EPS growth) but modest long-term expectations (8.9% five-year growth). Valuation appears reasonable with PE of 18.28 and PEG of 1.56, though the PEG suggests moderate overvaluation relative to sustainable growth rates. Additional metrics: PE Ratio: 18.28
News Sentiment
Gilead Sciences is making significant strides in expanding its therapeutic reach and global health impact. The biotech giant recently secured a major regulatory win with the FDA's approval of its drug for hepatitis delta virus (HDV), marking the first and only approved treatment for this deadly liver infection in the United States. This breakthrough approval was based on demonstrated reductions in HDV RNA and normalization of key liver enzymes, positioning Gilead as the leader in this previously untreatable condition. Beyond this regulatory success, the company has strengthened its oncology portfolio through the completion of its Tubulis acquisition, further diversifying its cancer treatment capabilities across different tumor types. Additionally, Gilead renewed its five-year collaboration with the World Health Organization to combat visceral leishmaniasis, reinforcing its commitment to global health initiatives. The company also highlighted promising lung cancer data for its Trodelvy treatment and showcased its long-acting HIV pipeline at recent investor conferences. These developments collectively demonstrate Gilead's strategic focus on addressing unmet medical needs while expanding its addressable market across infectious diseases and oncology, setting the stage for sustained growth in its core therapeutic areas.
Risk Assessment
Primary risks include revenue growth lagging industry peers and potential unsustainability of explosive near-term EPS growth projections. Moderate leverage (debt-to-equity 0.89) requires monitoring in rising rate environment. Mitigation comes from strong cash position ($9.8B), diversified pipeline, and proven operational excellence.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is GILD a halal stock?
No, Gilead Sciences, Inc. (GILD) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for GILD?
Gilead Sciences, Inc. (GILD) has a Plutrex AI rating of 82.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is GILD a good investment?
According to Plutrex AI, GILD has a Strong Buy rating (82.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in GILD?
US stocks like GILD can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in GILD?
Plutrex AI identifies the main risks for GILD by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.